Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) will host a virtual key opinion leader event on April 28, 2026 at 8:00 AM ET to discuss the unmet need and treatment landscape for hemodialysis patients with end-stage renal disease and provide an overview of its Acellular Tissue Engineered Vessel (ATEV) in arteriovenous access.
The event features KOLs Prabir Roy-Chaudhury, MD, PhD, FASN, and Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, and will include a live Q&A. The ATEV remains investigational for uses beyond the FDA extremity vascular trauma approval; interim V012 Phase 3 top-line results are expected this quarter.
Humacyte (Nasdaq: HUMA) on April 24, 2026 realigned ex-U.S. commercial rights to Symvess through an amended distribution agreement with Fresenius Medical Care. The amendment grants Humacyte exclusive distribution rights outside the U.S., with Fresenius entitled to low-single-digit royalties on Humacyte's net non-U.S. sales. U.S. distribution terms remain unchanged. The realignment is intended to support Humacyte's planned international expansion, advance discussions with potential corporate partners for indication-specific and regional rights, and enable previously announced initiatives in the Kingdom of Saudi Arabia and Israel. For uses beyond the FDA-approved extremity vascular trauma indication, Symvess remains investigational and is not approved for sale by the FDA or other regulators.
Humacyte (Nasdaq: HUMA) appointed Jim Mercadante as Chief Commercial Officer on April 22, 2026.
Mercadante brings more than 25 years of medtech commercial experience to lead U.S. Symvess expansion and broader ATEV platform commercialization as the company advances toward a planned BLA filing in dialysis.
Humacyte (Nasdaq: HUMA) announced that the Israel Ministry of Health accepted its Marketing Authorization Application for Symvess (acellular tissue engineered vessel) for arterial trauma repair and set a 180-working-day review period.
Acceptance references existing FDA approval for extremity vascular trauma and is described as a step in planned global expansion of Symvess.
Humacyte (Nasdaq: HUMA) reported $0.5M Q4 revenue and $2.0M for 2025, including $1.4M of Symvess sales. The company received a $1.475M purchase commitment in Saudi Arabia, submitted a Marketing Authorization Application in Israel, and secured DoD funding support.
Key milestones: top-line interim result from the V012 Phase 3 hemodialysis study expected by early June 2026 and planned BLA filing in H2 2026. Cash was $50.5M at year-end, with subsequent equity proceeds and a $40M initial tranche from a $77.5M credit facility.
Humacyte (Nasdaq: HUMA) appointed Rick McElheny as Senior Vice President of Business Development effective March 26, 2026. McElheny brings more than 15 years of corporate development and alliance management experience and will lead efforts to expand collaborations to commercialize Humacyte’s bioengineered tissue pipeline.
His prior roles include SVP of Corporate Development at Clearside and founder/VP of corporate development at Vidara, where he led transactions including a $660 million sale and over $250 million in out‑licensing deals.
Humacyte (Nasdaq: HUMA) will release fourth quarter and year‑end financial results for the period ended December 31, 2025 on March 27, 2026, and will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
The company emphasizes its commercial‑stage biotechnology platform and notes FDA approval of Symvess (ATEV) for vascular trauma in December 2024 and ongoing late‑stage trials in AV access and PAD.
Humacyte (Nasdaq: HUMA) received a binding minimum purchase commitment of $1.475 million for Symvess to support a clinical evaluation and outreach program in hospitals in the Kingdom of Saudi Arabia (KSA), announced March 19, 2026.
Humacyte will provide training personnel, will not negotiate commercialization rights in the KSA with other parties through July 2, 2026, and is negotiating a potential joint venture and license to commercialize Symvess in the KSA. Symvess remains investigational for uses beyond its FDA-approved extremity vascular trauma indication.
Humacyte (Nasdaq: HUMA) entered a registered direct offering to sell 25,000,000 shares, expected to raise gross proceeds of $20.0 million, with closing on or about March 20, 2026.
Proceeds are intended to fund commercialization of Symvess for vascular trauma, a BLA supplement filing and the upcoming Phase 3 hemodialysis read-out, pipeline development, and general corporate purposes.
Humacyte (Nasdaq: HUMA) submitted a Marketing Authorization Application (MAA) to the Israel Ministry of Health for Symvess, its acellular tissue engineered vessel for extremity arterial trauma repair, on March 17, 2026.
Humacyte is also pursuing hospital-by-hospital access in Israel before approval and plans broader Middle East expansion; clinical data cited include a retrospective 16-patient wartime series with 100% survival, zero amputations and zero conduit infections.